Today: 9 June 2026
New Zealand Stock Market Ends Higher as BlueScope Bid Sparks Steel Rally, Infratil Gains

New Zealand Stock Market Ends Higher as BlueScope Bid Sparks Steel Rally, Infratil Gains

Wellington, Jan 6, 2026, 23:00 NZDT — Market closed

New Zealand shares closed higher on Tuesday, led by steel-linked names after a takeover approach for Australia’s BlueScope Steel rippled across the sector. The benchmark S&P/NZX 50 index rose 76.35 points, or 0.56%, to 13,663.58, NZX data showed. 

The advance stretched the index’s winning streak to four sessions and left it about 0.6% below its 52-week high, according to Investing.com data. NZX’s all-materials sub-index jumped 3.1% on the day, reflecting the bid-driven lift in construction and steel exposures. 

BlueScope said it received an all-cash A$30-a-share proposal from Kerry Stokes-owned SGH and U.S. steelmaker Steel Dynamics that would split the company along geographic lines. BlueScope shares surged 21% in Sydney, Reuters reported, a move New Zealand traders treated as a read-through for local suppliers. 

Vulcan Steel (VSL) climbed 3.6% to NZ$8.40, while Fletcher Building (FBU) gained 1.6% to NZ$3.81 and Steel & Tube Holdings (STU) jumped 4.7% to 67 cents. “It’s a vote of confidence in those more cyclical industries that should perform well if the economy does what we’re hoping it will,” said Mark Lister, investment director at Craigs Investment Partners. nzx.com+1

BlueScope said it is “considering and evaluating” the approach and disclosed it had previously turned away several unsolicited bids. Steel Dynamics CEO Mark Millett said the carve-up would be “highly complementary” to the U.S. group’s existing operations. Reuters+1

Infrastructure investor Infratil (IFT) rose 2.6% to NZ$11.73 after it lifted the midpoint of an independent valuation for its CDC data centres stake to A$14.0 billion. “CDC’s valuation increased in the quarter, supported by an additional 40MW of previously announced contracted capacity,” Infratil said. nzx.com

Auckland International Airport (AIA) added 1.8% to NZ$8.50 and Fisher & Paykel Healthcare (FPH) edged up 0.4% to NZ$37.82. Turnover — the value of shares traded — was NZ$85.3 million on the main board, National Business Review reported.

Banks were the main drag, with Westpac Banking Corp (WBC) down 2.6% at NZ$44.14 and ANZ Group (ANZ) off 2.6% at NZ$41.31. The NZX all-energy index fell 2.0%, while Brent crude dipped to about $61.63 a barrel and the New Zealand dollar firmed to roughly 58 U.S. cents, the NBR report said.

But the steel rally leans on a deal that still faces due diligence and regulatory hurdles, and BlueScope has flagged “execution risk” around regulatory outcomes. Mark Gardner, CEO at MPC Markets, called the proposal “highly conditional and execution-heavy,” underscoring how quickly spillover trades can reverse if talks stall. Reuters+1

The NZX 50 finished just below its session high of 13,669 and a round-number 13,700 area; the intraday low near 13,556 marks first support traders will watch. Next up are U.S. job openings data due Wednesday, Jan. 7, and the U.S. payrolls report on Friday, Jan. 9, while local investors also have Fletcher Building’s half-year results pencilled in for Feb. 18. 

Stock Market Today

  • Aker BP Share Price Surges Amid Valuation Debate
    June 9, 2026, 11:54 AM EDT. Aker BP (OB:AKRBP) shares climbed to NOK347.7, marking a 55.05% total shareholder return over one year, outperforming peers in Norway's energy sector. Despite this momentum, the stock trades at an 8.6% premium over a fair value of NOK320.11, raising questions about valuation. The company aims to sustain production above 500,000 barrels per day past 2030, backed by projects like Yggdrasil and Johan Sverdrup, supporting revenue growth. Yet, potential risks include higher emissions costs and delays in key developments. Analysts offer cautious pricing, but a discounted cash flow (DCF) model from Simply Wall St suggests a much higher intrinsic value of NOK1,769.75, indicating significant undervaluation. Investors face a valuation divide between conservative targets and optimistic cash flow projections.

Latest articles

Paranovus Stock Rockets 620% as $195 Million Share-Sale Filing Changes the Story

Paranovus Stock Rockets 620% as $195 Million Share-Sale Filing Changes the Story

9 June 2026
Paranovus Entertainment shares soared 620% to $6.76 after filing to potentially sell up to $195 million in new stock—an amount far exceeding its $7.14 million market cap—raising major dilution risks for investors as the company eyes acquisitions but warns that future share sales could pressure the stock price or threaten operations.
Coupang Stock Gains as Privacy Ruling Approaches

Coupang Stock Gains as Privacy Ruling Approaches

9 June 2026
Coupang shares jumped 2% to $15.49, outperforming a falling market, as investors braced for South Korea’s privacy regulator to decide June 10 on possible sanctions over a data breach exposing 33.6 million records—a ruling that could trigger fines up to 3% of sales and impact the stock’s recovery.
AEP’s $78 Billion Grid Plan Spurs Data Center Hopes

AEP’s $78 Billion Grid Plan Spurs Data Center Hopes

9 June 2026
AEP lifted its five-year capital plan to $78 billion after signing 7 gigawatts of new large-energy project agreements, with 90% of 63 gigawatts of expected incremental load by 2030 tied to data centers; shares recently traded at $127.27, up 26.9% over 52 weeks, with analysts’ mean price target at $142.76, as investors weigh execution risks and a new data-center rate structure.
Dow climbs in New York, but gains may stall

Dow climbs in New York, but gains may stall

9 June 2026
Dow jumps 154.87 points as tech rebounds and oil prices drop, with chipmakers like Intel and Broadcom up sharply; investors brace for Wednesday’s key inflation data and next week’s Fed meeting, which could sway rate expectations and market direction.
U.S. Stocks Hit Records This Week — Why the S&P 500 and Nasdaq Rally Survived the Oil Shock

Dow Up While Nasdaq Dips; AI Rally Meets Inflation Data

9 June 2026
Nuvalent soared after GSK agreed to buy the cancer drug developer for $10.6 billion in cash, valuing shares at $124—a 40% premium to Monday’s close—while investors awaited Wednesday’s key inflation data that could impact market direction and tech stock stability.
L&T just hit ₹4,195: what the new 52-week high says about India’s blue-chip rally
Previous Story

L&T just hit ₹4,195: what the new 52-week high says about India’s blue-chip rally

Marks & Spencer (MKS.L) shares fall as Jan 8 Christmas trading update looms
Next Story

Marks & Spencer (MKS.L) shares fall as Jan 8 Christmas trading update looms

Go toTop